Novartis Pharmaceuticals Corporation and inventors Paul W. Manley, Ph.D., Wen-Chung Shieh, Ph.D., Paul Allen Sutton, Ph.D., Piotr H. Karpinski, Ph.D., Raeann Wu, Ph.D., Stéphanie Monnier, Ph.D., and Jörg Brozio, Ph.D., received an Edison Patent Award from the Research & Development Council of New Jersey in the pharmaceuticals category for "Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide" (U.S. Patent 8,163,904 B2), describing the pharmaceutical salt that is the approved form of Tasigna®, a cancer medication created for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase, and chronic phase and accelerated phase Ph+ CMLin adult patients resistant, or intolerant, to prior therapy. Novartis and its inventors were honored at the Council's 34th Patent Award Ceremony & Reception on November 7, 2013 at the Liberty Science Center. The Liberty Science Center is home to the nation's largest IMAX Theater, where this short original film paid tribute to the work of this patent and its inventors.

• published: 15 Nov 2013
• views: 5